11:21 AM EST, 02/13/2025 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) was last seen 12% after the company on Thursday said its third-quarter loss stayed constant.

The company, which is developing superkines, in the treatment of cancer, posted a loss of $5.2 million, or $0.07 per share, unchanged from the prior-year period.

Medicenna reported cash holdings of $30 million, as at Dec. 31, compared with $17 million at March 31, 2024, providing it with sufficient capital to see through the completion of the MDNA11 ABILITY-1 study, and through the middle of next year.

"We are thrilled about the year ahead as we build on the significant progress we achieved last year," said chief executive Dr. Fahar Merchant. "Our excitement is driven by the impressive response rates seen in the ABILITY-1 trial, particularly in the monotherapy arm where 5 patients responded to MDNA11 out of 20 patients with heavily pre-treated advanced solid tumors, including one complete response, despite all of them having failed prior checkpoint inhibitor therapies."

The company will present pharmacokinetic and pharmacodynamic data from the ABILITY-1 trial at the AACR-Immuno-Oncology Conference later this month and updated efficacy data at other medical conferences in the second quarter, a statement noted.

The company's shares were last seen up $0.15 to $1.42 on the Toronto Stock Exchange.

Price: 1.42, Change: +0.15, Percent Change: +11.81